Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

110.49
+1.311.20%
Post-market: 110.24-0.2500-0.23%19:35 EDT
Volume:273.50K
Turnover:30.13M
Market Cap:1.03B
PE:89.53
High:110.70
Open:109.16
Low:108.66
Close:109.18
52wk High:118.00
52wk Low:90.60
Shares:9.34M
Float Shares:9.34M
Volume Ratio:0.90
T/O Rate:2.93%
Dividend:2.14
Dividend Rate:1.94%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):142.30

Loading ...

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Oct 07

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Oct 07

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Oct 07

Morgan Stanley Adjusts Price Target on Eli Lilly to $1,430 From $1,419

MT Newswires Live
·
Oct 07

AlzeCure Pharma to Present at Redeye Neurology Day

Reuters
·
Oct 07

Deutsche Bank Keeps Their Sell Rating on Novo Nordisk (0QIU)

TIPRANKS
·
Oct 07

Will Drug Approvals Change Merck (MRK) Narrative

Simply Wall St.
·
Oct 07

AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says

MT Newswires Live
·
Oct 07

Novo Nordisk Probes Patient Priorities in German Hemophilia A Study

TIPRANKS
·
Oct 07

Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone

TIPRANKS
·
Oct 07

Novartis price target lowered to $156 from $170 at Morgan Stanley

TIPRANKS
·
Oct 06

General Medicine Raises $120 Mln to Build the Healthcare Store

Reuters
·
Oct 06

General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company

THOMSON REUTERS
·
Oct 06

European Shares Gain as Genmab Jumps, Bond Yields Retreat

Reuters
·
Oct 06

LIVE Markets-a Health Boost for the STOXX

Reuters
·
Oct 06

Genmab at 3-Year High After Blood Cancer Drug Combination Study Results

Reuters
·
Oct 06

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Reuters
·
Oct 06